lopinavir/ritonavir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 77 Diseases   69 Trials   69 Trials   4434 News 


«12345678910111213...4546»
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Trial completion:  TREATNOW: Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 (clinicaltrials.gov) -  Jan 26, 2023   
    P2,  N=452, Completed, 
    There is an urgent need for data on alternative antiretroviral regimens in infants with HIV/TB co-infection, including twice-daily dolutegravir. Active, not recruiting --> Completed
  • ||||||||||  CinnoVex (IFN-β-1a biosimilar) / CinnaGen
    Retrospective data, Journal:  Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study. (Pubmed Central) -  Jan 17, 2023   
    While features of the study design may have contributed to these findings, they nevertheless highlight the potentially complex mechanisms underpinning adverse birth outcomes and HIV. The study results showed the drug regimens 2 and 5 increased the days of hospitalization and hospitalization in ICU, respectively, while the other drug regimens had no significant effect on mortality and use a ventilator in the studied patients and none of the drug regimens had an effect on reducing mortality compared to other ones.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Lopinavir/Ritonavir in PLWH With High-Grade AIN (clinicaltrials.gov) -  Jan 13, 2023   
    P1,  N=30, Not yet recruiting, 
    Experience with LPV/r may be applicable to the use of nirmatrelvir/ritonavir, but larger multicenter studies are needed to confirm these findings. Trial completion date: Jul 2024 --> Jan 2025 | Initiation date: Jan 2023 --> Jul 2023 | Trial primary completion date: Jan 2024 --> Jul 2024
  • ||||||||||  Trial primary completion date:  RECOVERY: Randomised Evaluation of COVID-19 Therapy (clinicaltrials.gov) -  Jan 9, 2023   
    P2/3,  N=50000, Recruiting, 
    Trial completion date: Jul 2024 --> Jan 2025 | Initiation date: Jan 2023 --> Jul 2023 | Trial primary completion date: Jan 2024 --> Jul 2024 Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  Convalescent Plasma - Public Assistance / Paris Hospitals
    Clinical, Journal:  Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial. (Pubmed Central) -  Dec 17, 2022   
    Among critically ill patients with COVID-19 randomized to receive 1 or more therapeutic interventions, treatment with an IL-6 receptor antagonist had a greater than 99.9% probability of improved 180-day mortality compared with patients randomized to the control, and treatment with an antiplatelet had a 95.0% probability of improved 180-day mortality compared with patients randomized to the control. Overall, when considered with previously reported short-term results, the findings indicate that initial in-hospital treatment effects were consistent for most therapies through 6 months.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Retrospective data, Journal:  CD4(+) T Cell Count Progress and Influencing Factors of Recovery in AIDS Patients with Virological Failure in Sichuan Province: A Retrospective Cohort Study. (Pubmed Central) -  Dec 9, 2022   
    It was found that protective factors to increase CD4(+) T cell count (p < 0.05) including females, Yi people, married or cohabiting, educational level at primary school or above, initial and recent treatment with Tenofovir + Lamivudine + Nevirapine Wellen, the second-line regimen with lopinavir/ritonavir (LPV/r) and the treatment time is more than 24 months...Age, sex, ethnicity, marriage, education, disease status, treatment protocols, treatment time, initial CD4(+) T cell count, and virus subtype are the influencing factors of PLWH CD4(+) T cell count increase. The poor recovery of CD4(+) T cell count after treatment was observed in PLWH infected with CRF85_BC virus.
  • ||||||||||  lopinavir/ritonavir / Generic mfg.
    Journal:  The relationship between oxygen therapy, drug therapy, and COVID-19 mortality. (Pubmed Central) -  Dec 8, 2022   
    Body mass index (BMI) had no influence on mortality, as well as high flow oxygen therapy, Lopinavir-ritonavir (LPV/r) therapy, and the interferon-alpha add LPV/r therapy...In conclusion, the mortality was higher in older patients, higher in men, and lower in the low-flow oxygen therapy group. BMI had no influence on mortality, as well as high flow oxygen therapy, LPV/r therapy, and interferon-alpha add LPV/r therapy.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1). (Pubmed Central) -  Nov 29, 2022   
    Practice Point 11: Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting unless it is considered effective against a SARS-CoV-2 variant or subvariant locally in circulation...Practice Point 13: Do not use ciclesonide to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Practice Point 14: Do not use fluvoxamine to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
  • ||||||||||  Selzentry (maraviroc) / ViiV Healthcare, Isentress (raltegravir) / Merck (MSD)
    PK/PD data, Preclinical, Journal, IO biomarker:  Pharmacokinetics, the immunological impact and the effect on HIV ex-vivo infectivity of maraviroc, raltegravir and lopinavir in MSM using Post-exposure Prophylaxis. (Pubmed Central) -  Nov 24, 2022   
    Merging together changes in MMC in all arms, we found a positive correlation in the CD8 T-cell lineage between the infectivity at day 7 and activation (CD38+ r=0.43, p=0.025, DR+ r=0.547, p=0.003 and 38+DR+ r=0.526, p=0.05), senescence (CD57+CD28- r=0.479, p=0.012), naïve cells (RA+CCR7+ r=0.484, p=0.01) and CCR5 expression (r=0.593, p=0.001). We conclude that maraviroc in combination with tenofovir/emtricitabine was associated with viral suppression in rectal explants and that overall ex-vivo HIV infectivity correlated with activation and senescence in CD8 mucosal mononuclear cells.
  • ||||||||||  remdesivir / Generic mfg., favipiravir / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  Antiviral use in liver function abnormalities and Covid-19 patients: Serial cases. (Pubmed Central) -  Nov 23, 2022   
    One of the patients in the Lopinavir-Ritonavir group died while receiving treatment. SAR-CoV-2 is one of the risk factors that cause liver function abnormalities supported by anti-viral drugs that cause liver work to increase.
  • ||||||||||  Edurant (rilpivirine) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Higher prevalence of QTc interval prolongation among virologically suppressed older people living with HIV. (Pubmed Central) -  Nov 19, 2022   
    In multivariable analysis, older age (OR 1.07, 95% CI 1.02-1.12, p = 0.005), female sex (OR 1.69, 95%CI 1.01-2.82, p = 0.046) and increasing BMI (OR 1.08, 95%CI 1.01-1.15, p = 0.03) were associated with QTc interval prolongation. With every 1-year increase in age, the odds of QTc interval prolongation increased by 7%.
  • ||||||||||  hydroxychloroquine / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  Impact of COVID-19 and Antibiotic Treatments on Gut Microbiome: A Role for Enterococcus spp. (Pubmed Central) -  Nov 16, 2022   
    In this context, antibiotic treatment may shift the gut microbiome composition towards OBs, particularly Enterococcus. The impact of treatment-driven dysbiosis on OBs infections and long-term consequences needs further study to define the role of gut homeostasis in COVID-19 recovery and inform targeted interventions.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Actemra IV (tocilizumab) / Roche, JW Pharma, Spikevax (elasomeran) / Moderna
    Clinical Impact of Sars-Cov-2 Vaccination in COVID-19 Outcomes in Patients Diagnosed with Hematologic Malignancies: Real-World Evidence of Two Years of Pandemic (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_1922;    
    In this real-world analysis, and despite the heterogeneity of infection by different viral variants and treatment availability for COVID-19 during the evolution of the pandemic, vaccination has resulted widely effective at reducing need of hospitalization, severity and mortality of the SARS-CoV-2 infection in patients with HM. Patients who develop a suboptimal humoral immunogenicity after vaccination are at higher risk to develop a severe/critical infection and would benefit from an early intervention.
  • ||||||||||  Prezista (darunavir) / J&J, Olumiant (baricitinib) / Incyte, Eli Lilly
    Journal:  Potential interactions between antineoplastic agents and medicines used to treat Covid-19. (Pubmed Central) -  Nov 2, 2022   
    This study identified a considerable number of potential drug-drug interactions. In view of the vulnerability of patients with cancer, it is vital that health professionals carefully assess the risks and benefits of drug combinations.
  • ||||||||||  Arbidol (umifenovir) / Pharmstandard, Ingavirin (imidazolyl ethanamide pentandioic acid) / Myelo Therap, Valenta Pharm
    Retrospective data, Journal:  Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020 (Pubmed Central) -  Nov 2, 2022   
    Despite short follow-up duration, reduced ART adherence was significantly associated with emergent resistance and increased mortality. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.
  • ||||||||||  Journal:  Discovery of Novel HIV Protease Inhibitors Using Modern Computational Techniques. (Pubmed Central) -  Oct 28, 2022   
    HPS/002 and HPS/004 have been found to be most promising in terms of IC/percent inhibition (90.15%) of HIV-1 PR, in addition to their drug metabolism and safety profile. These hit candidates should be investigated further as possible HIV-1 PIs with improved efficacy and low toxicity through in vitro experiments and clinical trial investigations.
  • ||||||||||  Journal:  High-cited favorable studies for COVID-19 treatments ineffective in large trials. (Pubmed Central) -  Oct 27, 2022   
    Many clinical studies with favorable conclusions for largely ineffective coronavirus disease 2019 treatments are uncritically heavily cited and disseminated. Early observational studies and small randomized trials may cause spurious claims of effectiveness that get perpetuated.
  • ||||||||||  Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
    Review, Journal:  Molnupiravir in COVID-19: A scoping review. (Pubmed Central) -  Oct 27, 2022   
    On the basis of the limited evidence available as of now, molnupiravir could prove to be a promising oral therapy, worthy of further exploration of its utility for both treatment and prevention of COVID-19 in humans. Elaborate clinical evaluation is further warranted to confirm whether the results are replicable to the clinical scenario among outpatients to reduce the chance of progression to more severe disease.
  • ||||||||||  dexamethasone / Generic mfg., lopinavir/ritonavir / Generic mfg.
    Journal:  Unsupervised clustering reveals phenotypes of AKI in ICU COVID-19 patients. (Pubmed Central) -  Oct 25, 2022   
    When applied to an ICU cohort of COVID-19 patients, we were able to differentiate three groups of patients. Each expressed specific AKI characteristics and outcomes, which probably reflect a distinct pathophysiology.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection. (Pubmed Central) -  Oct 22, 2022   
    Drugs that prevent the virus from replicating include: Paxlovid, remdesivir, molnupiravir, favipiravir, ribavirin, and Kaletra...Lastly, drugs that target immune response regulation include interferons and the use of anti-inflammatory drugs such as dexamethasone...Learning more about these therapies helps raise awareness to the general population about the options available to them to aid in the reduction of the severity of COVID-19 infection. In this 'A Guide To' article, we provide an in-depth insight into the development of antiviral therapeutics against SARS-CoV-2 and their ability to help fight COVID-19.
  • ||||||||||  Viracept (nelfinavir) / ViiV Healthcare, Roche
    Review, Journal:  In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease. (Pubmed Central) -  Oct 21, 2022   
    Recent studies showed that many flavonoids such as hesperidin, amentoflavone, rutin, diosmin, apiin, and many other flavonoids have a higher affinity with M and lower binding energy than currently used drugs such as hydroxylchloroquine, nelfinavir, ritonavir, and lopinavir. Thus, these compounds can be developed as specific therapeutic agents against COVID-19, but need further in vitro and in vivo studies to validate these compounds and pave the way for drug discovery.